文献速递血管炎其他结缔组织病

英夫利西单抗与阿达木单抗治疗白塞病难治性葡萄膜炎的比较研究

Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
PubMed 文献 · Arthritis Rheumatol · 2019-10-21

该多中心开放标签研究比较了英夫利西单抗(IFX)与阿达木单抗(ADA)作为一线生物制剂治疗白塞病相关难治性葡萄膜炎1年的疗效,纳入177例患者(316只患眼),其中103例接受IFX、74例接受ADA。两组基线特征无显著差异,治疗1年后两组眼部参数均改善,但ADA组在玻璃体炎改善率、最佳矫正视力和药物留存率方面显著优于IFX组。

要点

  • ADA组1年药物留存率显著高于IFX组(95.24% vs 84.95%,P=0.042)。
  • ADA组玻璃体炎改善率显著优于IFX组(93.33% vs 78.95%,P=0.04)。
  • ADA组最佳矫正视力显著优于IFX组(0.81±0.26 vs 0.67±0.34,P=0.001)。

核心结论

  • IFX与ADA对白塞病相关难治性葡萄膜炎均有效,但ADA在1年随访时部分结局优于IFX。

研究设计与样本

  • 开放标签多中心研究,比较IFX与ADA作为一线生物制剂治疗白塞病相关难治性葡萄膜炎,共纳入177例患者(316只患眼),IFX组103例、ADA组74例。
  • IFX用法为3-5 mg/kg静脉给药,在第0、2、6周及之后每4-8周给药;ADA为40 mg皮下注射每两周一次,无负荷剂量。

主要发现

  • 治疗1年后两组所有眼部参数均改善,但ADA组前房炎症改善率92.31% vs IFX组78.18%(P=0.06)。
  • ADA组玻璃体炎改善率93.33% vs IFX组78.95%(P=0.04)。
  • ADA组最佳矫正视力均值±SD为0.81±0.26,IFX组为0.67±0.34(P=0.001)。
  • 黄斑厚度ADA组250.62±36.85 vs IFX组264.89±59.74(P=0.15),差异无统计学意义。
  • 视网膜血管炎改善率两组相似(ADA 95% vs IFX 97%,P=0.28),ADA组药物留存率95.24% vs IFX组84.95%(P=0.042)。

临床怎么用

  • 对于白塞病相关难治性葡萄膜炎,IFX和ADA均可作为一线生物制剂选择,ADA在玻璃体炎改善、视力预后和药物留存方面可能更具优势。

局限性

  • 本研究为开放标签设计,生物制剂选择由医师与患者协商决定,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as a first-line biologic drug over 1 year of treatment in a large series of patients with refractory uveitis due to Behçet's disease (BD). METHODS: We conducted an open-label multicenter study of IFX versus ADA for BD-related uveitis refractory to conventional nonbiologic treatment. IFX or ADA was chosen as the first-line biologic agent based on physician and patient agreement. Patients received 3-5 mg/kg intravenous IFX at 0, 2, and 6 weeks and every 4-8 weeks thereafter, or 40 mg subcutaneous ADA every other week without a loading dose. Ocular parameters were compared between the 2 groups. RESULTS: The study included 177 patients (316 affected eyes), of whom 103 received IFX and 74 received ADA. There were no significant baseline differences between treatment groups in main demographic features, previous therapy, or ocular sign severity. After 1 year of therapy, we observed an improvement in all ocular parameters in both groups. However, patients receiving ADA had significantly better outcomes in some parameters, including improvement in anterior chamber inflammation (92.31% versus 78.18% for IFX; P = 0.06), improvement in vitritis (93.33% versus 78.95% for IFX; P = 0.04), and best-corrected visual acuity (mean ± SD 0.81 ± 0.26 versus 0.67 ± 0.34 for IFX; P = 0.001). A nonsignificant difference was seen for macular thickness (mean ± SD 250.62 ± 36.85 for ADA versus 264.89 ± 59.74 for IFX; P = 0.15), and improvement in retinal vasculitis was similar between the 2 groups (95% for ADA versus 97% for IFX; P = 0.28). The drug retention rate was higher in the ADA group (95.24% versus 84.95% for IFX; P = 0.042). CONCLUSION: Although both IFX and ADA are efficacious in refractory BD-related uveitis, ADA appears to be associated with better outcomes than IFX after 1 year of follow-up.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, et al. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases. Arthritis Rheumatol. 2019. PMID: 31237427. doi:10.1002/art.41026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。